CoChat
Sign Up
Cited by 112Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesSkin Protection and Aging

Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: A randomized study

Wennberg, Ann-Marie, Stenquist, Bo, Stockfleth, Eggert, Keohane, Stephen, Lear, John T., Jemec, Gregor, Mork, Cato, Christensen, Eidi +5 more·2008·Transplantation
DOI 10.1097/tp.0b013e318180731e
Open this paper in CoChat — free account

Abstract

BACKGROUND: Organ transplant recipients on long-term immunosuppressive therapy are at increased risk of non-melanoma skin lesions. Repeated field photodynamic therapy using topical methyl aminolevulinate (MAL) may have potential as a preventive treatment. METHODS: This open randomized, intrapatient, comparative, multicenter study included 81 transplant recipients with 889 lesions (90% actinic keratoses (AK)]. In each patient, the study treatment was initially administered to one 50 cm area on the face, scalp, neck, trunk, or extremities (n=476 lesions) twice (1 week apart), with additional single treatments at 3, 9, and 15 months. On each occasion, the area was debrided gently and MAL cream (160 mg/g) applied for 3 hr, before illumination with noncoherent red light (630 nm, 37 J/cm2). The control, 50 cm2 area (n=413 lesions) received lesion-specific treatment (83% cryotherapy) at baseline and 3, 9, and 15 months. Additionally, all visible lesions were given lesion-specific treatment 21 and 27 months in both treatment and control areas. RESULTS: At 3 months, MAL photodynamic therapy significantly reduced the occurrence of new lesions (65 vs. 103 lesions in the control area; P=0.01), mainly AK (46% reduction; 43 vs. 80; P=0.006). This effect was not significant at 27 months (253 vs. 312; P=0.06). Hypopigmentation, as assessed by the investigator, was less evident in the treatment than control areas (16% vs. 51% of patients; P<0.001) at 27 months. CONCLUSION: Our results suggest that repeated field photodynamic therapy using topical MAL may prevent new AK in transplant recipients although further studies are needed.

Integrity signals

Registry

Crossref · 10.1097/tp.0b013e318180731e

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Wennberg et al. found that repeat MAL/PDT treatments 1 week apart at months 0, 3, 9, and 15 reduced the occurrence of new AKs in solid organ transplant recipients.

    “Wennberg et al. found that repeat MAL/PDT treatments 1 week apart at months 0, 3, 9, and 15 reduced the occurrence of new AKs in this special population [61].”

    From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [61]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Wennberg, A.-M., Stenquist, B., Stockfleth, E., Keohane, S., Lear, J. T., Jemec, G., Mork, C., Christensen, E., Kapp, A., Solvsten, H., Talme, T., Berne, B., & Forschner, T.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Charité – Universitätsmedizin Berlin (DE)
  • St. Mary's Hospital (GB)
  • Manchester Royal Infirmary (GB)
  • Roskilde Sygehus (DK)
  • St Olav's University Hospital (NO)
  • Medizinische Hochschule Hannover (DE)
  • Karolinska University Hospital (SE)
  • Uppsala University Hospital (SE)
Corresponding author
Wennberg, Ann-Marie
ORCID
Venue
Transplantation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2008-08-15
Volume
86
Issue
3
Pages
423-429
ISSN
0041-1337 (ISSN-L)
DOI
10.1097/tp.0b013e318180731e
OpenAlex
W2003383692
Cited by
112
References
40
Citations by year
2026: 1 · 2025: 6 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 12 · 2014: 11 · 2013: 7 · 2012: 13
FWCI
5.91
Type
journal article
Language
en
Open access
closed
Locations
  • Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
photodynamic therapy, methyl aminolevulinate, transplant recipients, actinic keratosis, immunosuppression, field therapy, cryotherapy, hypopigmentation, red light illumination
MeSH terms
Administration, Topical, Adult, Aged, Aminolevulinic Acid, Europe, Female, Humans, Immunosuppressive Agents, Keratosis, Male, Middle Aged, Photochemotherapy, Organ Transplantation, Treatment Outcome, Photosensitizing Agents, Cryotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review